Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cognition Therapeutics

Explore full profile

A drug discovery and development company that helps restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders

Town of Harrison, United StatesFounded 2007Biotech & Life Sciences
Valuation $49M Market cap · 2026
Total funding $50–100M Disclosed equity funding

About Cognition Therapeutics

Cognition Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company operates in the healthcare and biotechnology market, primarily targeting conditions such as Alzheimer's disease, dementia with Lewy bodies, and age-related macular degeneration. Cognition Therapeutics' core business model revolves around the discovery and development of small molecule drugs that modulate cellular damage response mechanisms. Their lead candidate, CT1812, is currently undergoing clinical trials and aims to displace toxic protein oligomers on neurons, thereby restoring normal cellular function. The company generates revenue through research grants, partnerships, and potential future sales of their therapeutic compounds. Cognition Therapeutics serves a global market, including patients, healthcare providers, and research institutions.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2007
Headquarters
Town of Harrison, United States
Listing
IPO 2021
Employees
29
Open positions
1
Dealroom signal
63.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Links
WebsiteLinkedInX

Latest news

Press, funding announcements and product moves mentioning Cognition Therapeutics.

See all news

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Aug 2025 $30M — Undisclosed ↗
POST IPO EQUITYOther financing Mar 2024 $12M — Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026 $0 — −$23M —
2025 $0 — −$23M —
2024 $0 — −$33M —
2023 $0 — −$26M —
2022 $0 — −$21M —
2021 — — −$13M —
2020 — — −$6M —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Cognition Therapeutics website traffic

Latest recorded traffic for Cognition Therapeutics is 5.2K monthly website visits, down 21.2% over the last three months. Cognition Therapeutics's team declined 19.4% over the past year.

Latest monthly visits5.2K 3-month web change-21.2% 1-year team growth-19.4%
Monthly website visitsOct 2017–Jul 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
WaveBreakSmall-molecule therapeutics for neurodegenerative diseases Cambridge, United Kingdom Operational 7 $40M $119M
TauRx PharmaceuticalsDeveloping tau aggregation inhibitors for neurodegenerative diseases Aberdeen, United Kingdom Operational
Amphista TherapeuticsNext-generation therapeutics for targeted protein degradation Great Abington, United Kingdom Operational
Proclara BiosciencesPioneering a new approach to treating neurodegenerative diseases Cambridge, United States Operational
NodTheraSmall molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and cancers Montrose, United Kingdom Operational
Unchained LabsHelping biologics researchers break free from tools that just don’t cut it Pleasanton, United States Acquired
Eikonizo TherapeuticsDeveloping therapies to improve the treatment of human disease, specifically neurodegenerative diseases Cambridge, United States Operational
Longboard PharmaceuticalsA clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases San Diego, United States Acquired
Showing 8 of the closest matchesCompare every metric →

Investors

28 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • National Institute on Aging
  • Michael J. Fox Foundation for Parkinson's Research

Series A15 investors entered at this stage

  • Ogden Capital
  • M5Invest Partners
  • Pittsburgh Life Sciences Greenhouse
  • Golden Seeds
  • Doughty Hanson Technology Ventures
  • Alzheimer's Drug Discovery Foundation
  • New York Angels
  • NuFund Venture Group
  • Maine Angels
  • Ariel Southeast Angel Partners
  • Scale Investors
  • Tech Coast Angels
  • Dolby Family Ventures
  • Accelerator Fund
  • Cowtown Angels

Series B and later1 investor entered at this stage

  • Innovation Works

Other known investors10 additional known investors

  • 3E Bioventures
  • Atlanta Technology Angels
  • Audrey's Kitchen
  • Bios Partners
  • BlueTree Allied Angels
  • iNetworks
  • Ly Tran
  • Next Act Fund
  • Small Business Innovation Research
  • Sofia Fund

Talent

Book a demo to see the people
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States95.7%
🇵🇭 Philippines4.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cognition Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cognition Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.